Catalytic ozonation by metal ions for municipal wastewater disinfection and simulataneous micropollutants removal

This work evaluated the effects of Fe2+, Co2+ and Al3+ in municipal wastewater disinfection through E.coli and Pseudomonas spp inactivation along with cellular adenosine triphosphate (ATP) depletion. Simultaneously, the effect of catalytic ozonation of secondary effluent on the removal of selected micropollutants with different ozone kinetics (acetamiprid, dichlorvos and atrazine) was evaluated. E.coli and Pseudomonas spp inactivation increased almost 20% with 1 mgL-1 Fe2+, Co2+, Al3+ and 40% with 10 mgL-1 Fe2+ compared with single ozonation. The bacteria reactivation after the treatments showed that Fe2+ was the most effective metal ion on inhibiting regrowth. The cellular ATP followed the same trend as the indicators microorganisms inactivation, with significant reduction of ATP over the treatment compared to single ozonation. Finally, the HO¿ exposure per consumed ozone ratio was applied for single ozonation, Fe2+/O3, Co2+/O3 and Al3+/O3 processes to evaluate and compare the contribution of radical pathway on micropollutants abatement

Metals as Catalysts for Ozonation

Ozonation is an efficient process for water and wastewater treatment, widely used for the disinfection and oxidation of organic pollutants. This process is effective, however, some pollutants are ozone-resistant. For better oxidation, enhanced production of hydroxyl radicals (HO•) can be obtained through the transition metals insertion in solution, known as homogeneous catalytic ozonation. These metals may react directly with O3 to produce HO• or interact with organics such as humic substances in the water matrix to promote O3 transformation to HO•. In this chapter, a short review of the homogeneous catalytic ozonation, including key aspects, such as pH effect, metals concentration, catalytic mechanisms, drawbacks of the homogeneous catalytic ozonation application, and the possible solution for it was provided

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Optimization of UV/H2O2 and ozone wastewater treatment by the experimental design methodology

The objective of this study was to optimize UV/H2O2 and ozonation systems by means of an experimental design using as a response the efficiency of the operational conditions to remove the methylene blue (MB) dye. Two classes of experimental planning were used: the Doehlert matrix (DM) and the central composite design (CCD). The most important variables for each process were hydrogen peroxide concentration, the ratio of illuminated volume/total volume of the reactor and recirculation flow rate for UV/H2O2, and ozone flow rate, consumed ozone and MB concentration for the ozonation. The DM was more efficient in optimizing the systems, since it used a smaller number of experiments and achieved similar results when compared to the CCD. After optimization, the disinfection efficiency of the systems was tested with secondary effluent evaluating the inactivation of microbiological indicators, Escherichia coli and total coliforms, using the optimized and the worst condition previously obtained with MB removal as response. The inactivation efficiencies in the optimum conditions were about 99%, allowing an efficient disinfection as well as the production of an effluent with quality to be reused according to specific legislations, while at the worse conditions, the inactivation did not reach standards for reuse40151910CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP306218/2014-32014/17774-1; 2016/07911-

Are iron chelates suitable to perform photo-fenton at neutral pH for secondary effluent treatment?

There have been concerns about which iron chelate is most suitable for application in the photo-Fenton process as well as the fate of these chelates after application. In this study, five chelating agents, i.e. citric acid (CA), oxalic acid (OA), ethylenediamine disuccinic acid (EDDS), ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), representing the most used iron chelates were assessed for suitability of application in homogeneous photo-Fenton-like process at pH of 7. The efficiency of the iron chelates were assessed in the disinfection of secondary effluent. The results for the disinfection and bacteria regrowth followed the order EDTA>OA>NTA>CA>OA. All the iron chelates were observed to have increased the COD of the effluent with EDDS having the highest COD contribution. The ability of the chelates to remove aromaticity was measured by the UV254 measurement. The efficiency of the chelates to remove aromaticity decreased in the order CA>EDDS>NTA>CA>OA. To determine the fate of the chelates, toxicity tests were conducted on the chelates before and after irradiation and the results revealed a decrease in toxicity after photoirradiation, implying the chelates were degraded and the products/intermediates produced were of less toxicity as compared to the parent compounds278CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP308914/2017-1; 424395/2016-92014/17774-

Stratified analyses refine association between TLR7 rare variants and severe COVID-19

Summary: Despite extensive global research into genetic predisposition for severe COVID-19, knowledge on the role of rare host genetic variants and their relation to other risk factors remains limited. Here, 52 genes with prior etiological evidence were sequenced in 1,772 severe COVID-19 cases and 5,347 population-based controls from Spain/Italy. Rare deleterious TLR7 variants were present in 2.4% of young (<60 years) cases with no reported clinical risk factors (n = 378), compared to 0.24% of controls (odds ratio [OR] = 12.3, p = 1.27 × 10−10). Incorporation of the results of either functional assays or protein modeling led to a pronounced increase in effect size (ORmax = 46.5, p = 1.74 × 10−15). Association signals for the X-chromosomal gene TLR7 were also detected in the female-only subgroup, suggesting the existence of additional mechanisms beyond X-linked recessive inheritance in males. Additionally, supporting evidence was generated for a contribution to severe COVID-19 of the previously implicated genes IFNAR2, IFIH1, and TBK1. Our results refine the genetic contribution of rare TLR7 variants to severe COVID-19 and strengthen evidence for the etiological relevance of genes in the interferon signaling pathway